Multicentre Trial Principal Investigators Claudio Andreoli e Alberto Costa Salvatore Maugeri Foundation I.R.C.C.S. Breast conservative surgery with and.

Slides:



Advertisements
Similar presentations
CORRADO TINTERRI Good afternoon, welcome to Humanitas Cancer Center, I thank the Steering committee for giving me the opportunity to talk to you about.
Advertisements

516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.
Breast Cancer. Introduction Most common female cancer Accounts for 32% of all female cancer 211,300 new cases yearly and rising 40,000 deaths yearly.
History of the randomized evidence on early breast cancer overall survival: Radiation vs no radiation after mastectomy L. Vakaet 2006.
Breast Cancer in Pregnancy
Giuliano Pre-SSO mins ASCO Z mins
Journal club Dr Eyad Al-Saeed Radiation Oncology 8-Sep-2007.
Breast Cancer Screening, Family History Assessment and New Innovations Miss Karina Cox Consultant Breast and Oncoplastic Surgeon.
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Radiotherapy in Carcinoma of the Breast Patrick S Swift, MD Director, Radiation Oncology Alta Bates Comprehensive Cancer Center Berkeley, CA.
“Conservative mastectomy” the nipple sparing tecnique Alberto Luini Senology Division European instiute of Oncology-Milan.
Breast Conservation Surgery
Margins: less is just as good
Hot topics in breast radiotherapy Mark Beresford.
Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;
Postmastectomy Radiation therapy (PMRT): Who needs it in 2008? Carol Marquez, M.D. Associate Professor, Department of Radiation Medicine Oregon Health.
Partial Breast Irradiation Carol Marquez, M.D. Associate Professor, Department of Radiation Medicine Oregon Health and Sciences University.
Study Of Letrozole Extension
Hypofractionated Radiation Therapy for Early Stage Breast Cancer Patrick J. Gagnon, M.D. Resident, PGY-4 Radiation Medicine, OHSU Providence Hospital Breast.
Elshami M.Elamin, MD Medical Oncologist Central Care Cancer Center Wichita, KS, USA
HERA: KEY DESIGN ELEMENTS, RESULTS AND FUTURE PLANS NSABP 17 SEPTEMBER 2005 Brian Leyland-Jones Minda De Gunzberg Professor of Oncology, McGill University,
Suggested guidelines for appropriate patient selection for patients undergoing Accelerated Partial Breast Irradiation at DMC. Tonya Echols Cole, MD.
SYB Case 2 By: Amy. History 63 y/o female History of left breast infiltrating duct carcinoma s/p mastectomy in 1996 and chemotherapy ER negative, PR negative,
Intergroup trial CALGB 80101
Breast Carcinoma. Anatomy Epidemiology: 10% 17.1/10 28/10 46/ m world wide 6% develop cancer of the breast in their lifetime. 50,000 to 70,000.
Long-term follow-up of a prospective trial of pre-operative external-beam radiation and post-operative brachytherapy for retroperitoneal sarcoma LA Mikula,
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Management of DCIS KWH Experience Dr. Carmen Ho.
Controversies in Radiation Therapy for Breast Cancer?
Radiation Breast Oncology Highlights of SABC 2006 Alison Bevan, MD PhD UCSF Radiation Oncology January, 2007.
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
Clinical Trials Evaluating the Role of Sentinel Node Resection in Patients with Early-Stage Breast Cancer Krag DN et al. Proc ASCO 2010;Abstract LBA505.
Targeted Intraoperative Radiotherapy versus Whole Breast Radiotherapy for Breast Cancer (TARGIT-A Trial): An International, Prospective, Randomised, Non-Inferiority.
TREATMENT Mastectomy -traditionally, treatment of breast ca has been surgical -19 century, surgical treatment : local excision ~ total mastectomy : radical.
CHANGING PARDIGMS IN BREAST SURGERY
Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.
Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer Jacques Bernier, M.D., Ph.D., Christian Domenge,
Bladder cancer is the second most common cancer of the genitourinary tract. The incidence is higher in whites than in African Americans. The average age.
1789 patients, 1982 – 1989, premenopausal, node + or Tumor > 5cm, M0 Total mastectomy, level I + II (partly) + CMF +/- 50Gy/25fx (electrons + photons)
DL Wickerham MD Deputy Chairman NRG Oncology Oct 5, 2015
Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, MD 1, Bruce.
THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.
Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC randomised trial From.
‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
Carboplatin Not Inferior to Radiation as Adjuvant Therapy for Stage I Seminoma Slideset on: Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose.
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann Journal.
Annals of Oncology 24: 2206–2223, 2013 R3 조영학
Treatment Options for Postmenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Recent Trials and Future Directions Harold Burstein,
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
ABSTRACT Purpose This retrospective review was conducted to determine if delay in the start of radiotherapy after conservative breast surgery had any detrimental.
PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,
The New trends in the Management of Breast Cancer 謝渙發 桃園縣醫師公會監事 怡仁綜合醫院副院長 教育部部定助理教授 國防醫學院外科學系臨床教授.
RCR breast radiotherapy consensus guidelines
Surgical Management of the Breast in Breast Cancer
But how to treat those with positive SLNB? Results and Discussion
Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.
20-Year Risks of Breast-Cancer Recurrence
THE LANCET Oncology Volume 19, No. 1, p27–39, January 2018
Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &
Presentation transcript:

Multicentre Trial Principal Investigators Claudio Andreoli e Alberto Costa Salvatore Maugeri Foundation I.R.C.C.S. Breast conservative surgery with and without RT in women aged with early breast cancer R Studio

Study Background  Breast conservative surgery (CS) followed by irradiaton of the remaining breast tissue (CS+RT) is generally accepted as the treatment of choice for the vast majority of patients with early stage breast cancer  It results in advantages of improved cosmesis and quality of life as compared to mastectomy without exposing patients to a higher risk of breast cancer deaths R Studio

PartecipatingCentres N° pts Pavia176 Ortona110 Bergamo109 Reggio Emilia 80 Alba65 Bologna56 Ciriè35 San Giovanni Rotondo 31 Torino26 Udine21 Roma20 TOTAL749 Total randomized pts at the Start : January 2001 End : December R Studio

Aims of the study Primary Aim Cumulative incidence of local recurrences after CS+RT vs CS alone Secondary Aims Disease-free survival Distant disease-free survival Overall survival Ancillary studies Long-term sequelae, costs to the NHS R Studio

Quadrantectomy R R RT of the breast No RT Axillary dissection / SNB Adjuvant treatment according to Center policy and related to axillary nodal status and biological tumor parameters Histology R Studio Study design

RATIONAL RATIONAL The rational of the study is to define a reliable RISK FACTOR PROFILE to determine a group of patients at “ LOW RISK “ for local recurrence in whom radiation therapy could be avoided. The rational of the study is to define a reliable RISK FACTOR PROFILE to determine a group of patients at “ LOW RISK “ for local recurrence in whom radiation therapy could be avoided R Studio

INCLUSION CRITERIA INCLUSION CRITERIA Age : > 55 < 75 yrs Maximum tumor size 2.5 cm. Unifocal infiltrating Ca of any grading and hormone receptor status Axillary nodes status pN0-pN1bi No extensive intraductal component No extensive peritumoral vascular invasion Age : > 55 < 75 yrs Maximum tumor size 2.5 cm. Unifocal infiltrating Ca of any grading and hormone receptor status Axillary nodes status pN0-pN1bi No extensive intraductal component No extensive peritumoral vascular invasion R Studio

INCLUSION CRITERIA INCLUSION CRITERIA No distant disease No any clinical condition that can interfere with radiation treatment and standard follow-up No previous history of malignant diseases except for skin basocellular carcinoma, in situ ca of the cervix No previous oncological treatment No distant disease No any clinical condition that can interfere with radiation treatment and standard follow-up No previous history of malignant diseases except for skin basocellular carcinoma, in situ ca of the cervix No previous oncological treatment R Studio

SURGERY SURGERY TUMOUR DIAMETER > 1,5 CM. Patients underwent the classical Veronesi quadrantectomy wich includes the removal of the tumor with a large rim of healthy tissue, the skin above the tumor and the underlying muscolar fascia. TUMOUR DIAMETER < 1,5 CM A limited resection was performed. Respect the Holland histo-pathological criteria and remove the skin above the tumor and the underlying muscolar fascia R Studio

RADIOTHERAPY RADIOTHERAPY Photon beam of 4 -6 MV (Linear acc.) 50 Gy. Breast 10 Gy di Boost tumour bed Opposed tangential fields 2 Gy / day ( 5 days a week ) Energy Dosage Technique Fraction R Studio

Patient population and follow-up examinations A total of 749 patients were enrolled in 11 participating centers from January 2001 and December 2005 Treatment allocation was centralized and stratified per site Follow-up included physical examination every 6 mos for the first 5 years and annually thereafter and radiological examinations once a year to include bilateral breast US and mammography R Studio

STATISTICAL ANALYSIS AND DATA CENTRE Pinuccia VALAGUSSA National Cancer Institute, MILAN

Analysis of Primary and Secondary Aims Cut-off date for present analysis was November 2007 Median follow-up was 53 months (lead 83 mos) Analyses were conducted according to the Intent-To-Treat (ITT) principle Total number of events local recurrence 10; regional recurrence 5; distant relapse 20; contralateral breast 4; other primary cancer ( no breast )12; death in the absence of cancer R Studio

Main Patient Characteristics in % CS alone (376 patients) CS+RT (373 patients) Age > 65 years5046 pT2 lesions1412 Ductal ca.7375 Lobular ca.1514 pN positive1614 ER negative8.510 PgR negative R Studio

#% 95% CI #% Total Age < 66 yr > 65 yr > 65 yr (0-3.0) pT1pT pN-pN ER positive ER negative Actuarial Risk of Local Recurrence CS (376 patients)CS+RT (373 patients) R Studio

5-yr Cumulative Incidence of Local Recurrence (ITT analysis) Years % 2.5% CS 2.5% CS+RT 0.7% P = R Studio

Distant Disease-Free Survival Probability Years CS 96.5% CS+RT 96% R Studio

Overall Survival Probability Years CS 96% CS+RT 95% R Studio

QUART : incidenza cumulativa recidive locali (2.333 casi INT – 1972 – 1984) anni probabilità %

Conclusions Present data indicate that breast irradiation Present data indicate that breast irradiation after conservative surgery might be avoided after conservative surgery might be avoided in selected patients with early breast cancer aged years in selected patients with early breast cancer aged years without exposing them to an increased risk without exposing them to an increased risk of local and distant disease recurrence. of local and distant disease recurrence. Longer follow-up is needed to consolidate this preliminary results. Longer follow-up is needed to consolidate this preliminary results R Studio

If RT could be omitted …. 1) broader use of breast conserving treatment 1) broader use of breast conserving treatment 2) no complications and risks of RT 2) no complications and risks of RT 3) better cosmetic result 3) better cosmetic result 4) easier diagnosis of local recurrence 4) easier diagnosis of local recurrence 5) easier reconstruction after MX in case of LR 5) easier reconstruction after MX in case of LR 6) cost reduction for the NHS 6) cost reduction for the NHS 7) reduction of waiting list 7) reduction of waiting list 8) better QoL for the patient 8) better QoL for the patient 9) avoidance of indirect costs for the patient 9) avoidance of indirect costs for the patient 10) earlier return to work or active life

Acknowledgements and to the study investigators Claudio Amanti (Roma), Nicoletta Biglia (Torino), Marina Bissolotti (Pavia), Ettore Cianchetti (Ortona), Giuliana Gentile (Udine), Privato Fenaroli (Bergamo), Vinicio Fosser (Vicenza), Mirella Merson (Bergamo), Roberto Murgo (S.G.Rotondo), Maria Carmela Orlandi (Cirié), Claudio Pedrazzoli (Reggio Emilia), Gianpaolo Sacchetto (Alba), Piero Sismondi (Torino), Carlo Tondini (Bergamo), Mario Taffurelli (Bologna) and to the study investigators Claudio Amanti (Roma), Nicoletta Biglia (Torino), Marina Bissolotti (Pavia), Ettore Cianchetti (Ortona), Giuliana Gentile (Udine), Privato Fenaroli (Bergamo), Vinicio Fosser (Vicenza), Mirella Merson (Bergamo), Roberto Murgo (S.G.Rotondo), Maria Carmela Orlandi (Cirié), Claudio Pedrazzoli (Reggio Emilia), Gianpaolo Sacchetto (Alba), Piero Sismondi (Torino), Carlo Tondini (Bergamo), Mario Taffurelli (Bologna) To the 749 women participating in the study R Studio